Linked Life Data

18625854

Source:http://linkedlifedata.com/resource/pubmed/id/18625854

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-7-15
pubmed:abstractText
Recent therapeutic advances have improved standard treatment for patients with newly diagnosed glioblastoma. Unfortunately, even with these improvements, only a fraction of patients derive significant benefit and experience prolonged survival. These findings are consistent with long-standing clinical and recent molecular evidence that subtypes of glioblastoma exist with differing survival rates and response to treatment. However, patients with newly diagnosed glioblastoma are currently treated in a uniform fashion, without regard for potential underlying differences in molecular alterations or prognosis. In this review, we will discuss recent progress toward the identification of robust and clinically relevant molecular subgroups of glioblastoma and initial steps in using this information to individualize therapy and overcome treatment resistance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1538-3687
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
877-83
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Molecular predictors in glioblastoma: toward personalized therapy.
pubmed:affiliation
Department of Neuro-oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030, USA. hcolman@mdanderson.org
pubmed:publicationType
Journal Article, Review